This week in techniques



Licensing status

Publication and contact information

Drug platforms

Controlled Fab-arm exchange (cFAE) approach to develop bispecific antibodies for therapeutic use

In vitro and mouse studies identified a method to develop bispecific antibodies as therapeutics. The cFAE method involved expressing matched mutant methyl domains in two IgG1 antibodies and combining the antibodies with a weak reducing agent to preserve the heavy-chain and light-chain pairings. Bispecific antibodies were designed including those that target both CD20 and HER2 (EGFR2; ErbB2; neu), as well as those that target HER2 and CD3. In cancer cells and in mice xenograft models for gastric carcinoma, the HER2- and CD3-targeting antibody decreased cancer cell survival compared with a control antibody. Next steps include developing bispecific antibody therapeutic candidates.

SciBX 6(11); doi:10.1038/scibx.2013.275
Published online March 21, 2013

Patent applications filed; licensed to Novartis AG, Janssen Pharmaceuticals N.V., Kyowa Hakko Kirin Co. Ltd. and an undisclosed company for specific programs; available for licensing

Labrijn, A.F. et al. Proc. Natl. Acad. Sci. USA; published online March 11, 2013;
Contact: Paul W.H.I. Parren, Genmab A/S, Brooklyn Park, Minn.